SCHEMBL84451

SCHEMBL84451

CC(C)c1ccncn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448509 1.00
Water SCHEMBL8524004 0.98 HSP90AA1 (0.41)
SCHEMBL28803015 0.81
SCHEMBL21918669 0.81
SCHEMBL3154891 0.81
SCHEMBL19413126 0.81 HSP90AA1 (0.39)
SCHEMBL3718708 0.81
SCHEMBL29857995 0.81
SCHEMBL31291331 0.81
SCHEMBL5340555 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116924976-A Diaryl heterocyclic amine compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2023-10-24 CN claimed
CN-103022556-A Lithium-ion battery and electrolyte thereof NINGDE AMPEREX TECHNOLOGY LTD 2013-04-03 CN claimed
US-12466804-B2 Cyclobutyl carboxylic acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-11 US disclosed
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 US disclosed
US-20240239835-A9 NEUROACTIVE STEROIDS AND THEIR METHODS OF USE SAGE THERAPEUTICS, INC. 2024-07-18 US disclosed
WO-2024151833-A1 SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS, LLC (US) 2024-07-18 WO disclosed
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20240228491-A1 METHIONINE ADENOSYLTRANSFERASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
WO-2002090328-A1 THE PREPARATION OF SUBSTITUTED PYRIDINES UTILIZING NITRIC AND AN ANHYDRIDE REILLY INDUSTRIES, INC. (US) 2002-11-14 WO disclosed
CN-1372552-A Pyrimidine derivatives and herbicides containing the same KUMIAL CHEMICAL INDUSTRY CO LT (JP) 2002-10-02 CN disclosed
CN-1029231-C Preparation method of triazole antifungal agent PFIZER (US) 1995-07-05 CN disclosed
US-5364938-A Triazole antifungal agents PFIZER INC. (US) 1994-11-15 US disclosed
EP-0357241-B1 Triazole antifungal agents PFIZER LTD (GB) 1994-02-16 EP disclosed
US-5206364-A Triazole antifungal agents PFIZER INC. (US) 1993-04-27 US disclosed
US-5116844-A TRIAZOLE ANTIFUNGAL AGENTS PFIZER INC. (US) 1992-05-26 US disclosed
CN-1040795-A The preparation method of triazole species antimycotic agent PFIZER (US) 1990-03-28 CN disclosed
EP-0357241-A1 Triazole antifungal agents Pfizer Limited (GB) 1990-03-07 EP disclosed